Source: MarketScreener

Myovant Sciences: Myovant Sciences Presents Additional Data on Relugolix Combination Therapy from Phase 3 LIBERTY Studies in Women with Uterine Fibroids and from Ovulation Inhibition Study

(marketscreener.com) Data from Phase 3 LIBERTY program show improvement in patient-reported outcomes in addition to improvement in hemoglobin levels in anemic womenDetailed data from ovulation inhibition study demonstrate 100% ovulation inhibition and 100% return of ovulation upon treatment discontinuationFindings presented during European Society of Human...https://www.marketscreener.com/MYOVANT-SCIENCES-LTD-31698733/news/Myovant-Sciences-Presents-Additional-Data-on-Relugolix-Combination-Therapy-from-Phase-3-LIBERTY-Stud-30881946/?utm_medium=RSS&utm_content=20200706

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Lynn Seely's photo - President & CEO of Myovant Sciences

President & CEO

Lynn Seely

CEO Approval Rating

89/100

Myovant Sciences is a biopharmaceutical company that develops and commercializes therapeutics for the treatment of fibroids and prostate cancer. Read more